Get the Stockscreener App
28.77
0.91%
0.26
Mineralys Therapeutics Inc stock is traded at $28.77, with a volume of 1.13M.
It is up +0.91% in the last 24 hours and down -6.04% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$28.51
Open:
$28.82
24h Volume:
1.13M
Relative Volume:
0.91
Market Cap:
$2.28B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-10.54
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-1.57%
1M Performance:
-6.04%
6M Performance:
-13.13%
1Y Performance:
+190.02%
1-Day Range:
$27.20
$29.06
1-Week Range:
$27.20
$29.61
52-Week Range:
$9.6935
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
28.77 | 2.26B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4%Should You Sell? - MarketBeat
A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism - Sahm
MLYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Citigroup Inc. - MarketBeat
Chart Watch: Can Mineralys Therapeutics Inc expand its profit marginsJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
MLYS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Stock Traders Buy High Volume of Mineralys Therapeutics Call Options (NASDAQ:MLYS) - MarketBeat
Biotech Mineralys gives new hire 27,920 options, 20,940 restricted stock units - Stock Titan
Should Mineralys’ New Shelf Registration and ESOP Offering Reshape How MLYS Investors View Its Capital Strategy? - Sahm
Investment Recap: How does Mineralys Therapeutics Inc score in quality rankingsMarket Risk Analysis & High Accuracy Trade Alerts - baoquankhu1.vn
MLYS Technical Analysis & ETF Price Forecast - Intellectia AI
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Biotech Gem with 77% Upside Potential - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Greenland Capital Management LP - MarketBeat
Mineralys Therapeutics (MLYS) insider reports option, RSU grants and transfers - Stock Titan
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics (MLYS) director awarded options and RSUs in Form 4 - Stock Titan
Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings - TipRanks
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505 - Investing.com Nigeria
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505 By Investing.com - Investing.com UK
David Malcom Rodman Sells 417 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Trial Recognition Highlights NDA Path And Dilution Considerations - Yahoo Finance
Mineralys Therapeutics Grants Inducement Equity Awards to Two New Employees - MyChesCo
Mineralys Therapeutics, Inc. (MLYS): An 85.82% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance
Breakouts Watch: What’s Mineralys Therapeutics Inc.’s historical returnJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Big Picture: Is SCHWPRD attractive for institutional investorsProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Momentum Shift: How does Mineralys Therapeutics Inc score in quality rankingsPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Why (MLYS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How sensitive is Mineralys Therapeutics Inc. to inflationJuly 2025 EndofMonth & Verified Short-Term Trading Plans - mfd.ru
What are the future prospects of Mineralys Therapeutics Inc.Market Growth Report & Verified Stock Trade Ideas - mfd.ru
Mineralys Therapeutics MLYS officer sells $569k in stock - Investing.com Nigeria
David Malcom Rodman Sells 14,055 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS officer sells $569k in stock By Investing.com - Investing.com UK
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys Therapeutics (MLYS) insider files to sell 14,055 shares - Stock Titan
Mineralys Therapeutics Breaks Below 200-Day Moving AverageNotable for MLYS - Nasdaq
How strong is Mineralys Therapeutics Inc. stock balance sheetInsider Selling & Daily Profit Focused Screening - mfd.ru
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 6,349 Shares - MarketBeat
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys Therapeutics (MLYS) insider plans NASDAQ sale after option exercise - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Is Mineralys Therapeutics Inc. a top pick in the sector2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Candriam S.C.A. - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 60% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
How cyclical is Mineralys Therapeutics Inc.’s revenue streamJuly 2025 Chart Watch & Verified Stock Trade Ideas - mfd.ru
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS) - MarketBeat
Panic Selling: How sensitive is Mineralys Therapeutics Inc to inflationJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is Mineralys Therapeutics Inc. stock a defensive play in 20252025 Fundamental Recap & Low Drawdown Momentum Ideas - mfd.ru
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):